MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-19-2026
Eton Pharmaceuticals Retained Earnings 2011-2026 | ETON
Retained earnings — this is the portion of a company’s net profit that has not been distributed to shareholders as dividends but remains at the company’s disposal for future use. It is also referred to as retained income or accumulated earnings.Possible uses include
- reinvestment in development (R&D, equipment, marketing)
- debt repayment
- acquisition of other companies
- creation of reserves for the future
A high level of retained earnings indicates that the company is in a growth phase, accumulating capital and prioritizing reinvestment over dividend payouts. Conversely, low or negative retained earnings may suggest either a generous dividend policy, in which all profits are distributed to shareholders, or ongoing losses that reduce the overall financial result.
The presence of retained earnings does not indicate that the company has available cash — it is solely an accounting figure reflecting the accumulated portion of net profit remaining after dividends have been paid. Therefore, it is important for investors to analyze not only the amount of retained earnings, but also how effectively it is used to develop the business, reduce debt, or build financial stability.
Annual Retained Earnings Eton Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -112 M | -108 M | -104 M | -103 M | -94.1 M | -92.2 M | -64.2 M | -45.9 M | -8.64 M | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -8.64 M | -112 M | -81.4 M |
Quarterly Retained Earnings Eton Pharmaceuticals
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -114 M | -112 M | -109 M | -108 M | -107 M | -108 M | -105 M | -104 M | -102 M | -101 M | -106 M | -103 M | -104 M | -101 M | -99.4 M | -94.1 M | -95.2 M | -89.1 M | -87 M | -92.2 M | -92.2 M | -92.2 M | -92.2 M | -64.2 M | -64.2 M | -64.2 M | -64.2 M | -45.9 M | -45.9 M | -45.9 M | -45.9 M | -8.64 M | -8.64 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -8.64 M | -114 M | -84.1 M |
Retained Earnings of other stocks in the Biotechnology industry
| Issuer | Retained Earnings | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
-158 M | - | 2.43 % | $ 254 M |  Germany |
 |
Autolus Therapeutics plc
AUTL
|
-1.39 B | $ 1.35 | -2.91 % | $ 359 M |  Britain |
 |
Coherus BioSciences
CHRS
|
-1.38 B | $ 1.61 | -3.59 % | $ 189 M |  USA |
 |
I-Mab
IMAB
|
-8.33 B | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
5.24 B | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
-405 M | - | 2.54 % | $ 160 B |  France |
 |
Biophytis SA
BPTS
|
-17.1 M | - | -13.47 % | $ 169 M | France |
 |
Catalyst Pharmaceuticals
CPRX
|
474 M | $ 24.88 | -0.4 % | $ 3.04 B | USA |
 |
Corbus Pharmaceuticals Holdings
CRBP
|
-555 M | $ 10.02 | -1.16 % | $ 133 M | USA |
 |
Midatech Pharma plc
MTP
|
-122 M | - | -18.52 % | $ 27.3 M | Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-108 M | - | -1.52 % | $ 24.7 M | USA |
 |
Cardiff Oncology
CRDF
|
-430 M | $ 1.57 | -0.63 % | $ 105 M | USA |
 |
Acorda Therapeutics
ACOR
|
-1.19 B | - | -24.86 % | $ 820 K | USA |
 |
Alterity Therapeutics Limited
ATHE
|
-182 M | $ 3.65 | 1.3 % | $ 8.78 B |  Australia |
 |
Advaxis
ADXS
|
-197 M | - | -9.65 % | $ 45.9 M | USA |
 |
DBV Technologies S.A.
DBVT
|
-393 M | $ 20.25 | -0.54 % | $ 2.83 B | France |
 |
Adverum Biotechnologies
ADVM
|
-1.07 B | - | - | $ 86.2 M | USA |
 |
Aytu BioScience
AYTU
|
-334 M | $ 2.55 | -4.14 % | $ 16 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
69.4 M | - | - | - |  Russia |
 |
Dyadic International
DYAI
|
-93.5 M | $ 0.87 | - | $ 31.5 M | USA |
 |
Aeterna Zentaris
AEZS
|
-335 M | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
-63.5 M | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-1.13 B | - | - | $ 1.01 B | USA |
 |
Entera Bio Ltd.
ENTX
|
-72.9 M | $ 1.17 | -2.1 % | $ 64 M |  Israel |
 |
Equillium
EQ
|
-216 M | $ 2.0 | -0.5 % | $ 115 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-308 M | - | - | $ 26.5 M | USA |
 |
Evogene Ltd.
EVGN
|
-179 M | $ 0.8 | 2.49 % | $ 27.9 M | Israel |
 |
AIkido Pharma
AIKI
|
-268 M | - | 1.93 % | $ 17.4 M | USA |
 |
Fate Therapeutics
FATE
|
-1.53 B | $ 1.15 | -3.78 % | $ 137 M | USA |
 |
Forte Biosciences
FBRX
|
-223 M | $ 26.15 | -1.1 % | $ 339 M | USA |
 |
Aptose Biosciences
APTO
|
-566 M | - | -45.71 % | $ 1.2 M | Canada |
 |
Fennec Pharmaceuticals
FENC
|
-229 M | $ 6.2 | -3.43 % | $ 177 M | USA |
|
Foghorn Therapeutics
FHTX
|
-632 M | $ 4.75 | -2.59 % | $ 299 M | USA |
 |
Amicus Therapeutics
FOLD
|
-2.77 B | $ 14.46 | 0.03 % | $ 4.46 B | USA |
 |
Akero Therapeutics
AKRO
|
-826 M | - | - | $ 3.67 B | USA |
 |
CureVac N.V.
CVAC
|
-1.06 B | - | - | $ 867 M | Germany |
 |
BioNTech SE
BNTX
|
-410 M | $ 88.37 | -3.19 % | $ 27.2 B | Germany |
 |
Akari Therapeutics, Plc
AKTX
|
-265 M | $ 3.52 | -0.56 % | $ 237 B | Britain |
 |
Akouos
AKUS
|
-168 M | - | 0.23 % | $ 488 M | USA |
 |
Fulcrum Therapeutics
FULC
|
-594 M | $ 7.45 | -4.85 % | $ 472 K | USA |
 |
Galectin Therapeutics
GALT
|
-433 M | $ 2.38 | -7.03 % | $ 152 M | USA |
 |
Allakos
ALLK
|
-1.12 B | - | - | $ 28.6 M | USA |
 |
Allena Pharmaceuticals
ALNA
|
-246 M | - | 3.16 % | $ 1.9 M | USA |
 |
Alnylam Pharmaceuticals
ALNY
|
-6.7 B | $ 315.4 | -4.52 % | $ 41.3 B | USA |
 |
Alpine Immune Sciences
ALPN
|
-224 M | - | - | $ 2.17 B | USA |
 |
Gilead Sciences
GILD
|
13.7 B | $ 138.37 | -1.26 % | $ 172 B | USA |
 |
Galmed Pharmaceuticals Ltd.
GLMD
|
-200 M | $ 0.54 | 4.26 % | $ 503 K | Israel |
 |
Aileron Therapeutics
ALRN
|
-401 M | - | 10.36 % | $ 9.8 M | USA |
 |
Genmab A/S
GMAB
|
7.11 B | $ 27.13 | -2.25 % | $ 17 B |  Danmark |
 |
AlloVir
ALVR
|
-160 M | - | 4.14 % | $ 49.1 M | USA |